MindMaze Therapeutics Holding (CHIX:MMTXZ) Net Margin %: -1,542.99% (As of Dec. 2025)


CHIX:MMTXZ MindMaze Therapeutics Holding SA CHIX:MMTXZ
15 GF Score
Price CHF0.21
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Net Margin %?

MindMaze Therapeutics Holding CHIX:MMTXZ +4.74% 15 Net Margin % is -1,542.99% as of Dec. 2025. GuruFocus rates CHIX:MMTXZ with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, MindMaze Therapeutics Holding ranks worse than 82.48% on this metric.

Net margin is calculated as Net Income divided by its Revenue. MindMaze Therapeutics Holding's Net Income for the six months ended in Dec. 2025 was CHF-9.91 Mil. MindMaze Therapeutics Holding's Revenue for the six months ended in Dec. 2025 was CHF0.64 Mil. Therefore, MindMaze Therapeutics Holding's net margin for the quarter that ended in Dec. 2025 was -1,542.99%.

The historical rank and industry rank for MindMaze Therapeutics Holding's Net Margin % or its related term are showing as below:

CHIX:MMTXz' s Net Margin % Range Over the Past 10 Years
Min: -1542.99   Med: -1542.99   Max: -1542.99
Current: -1542.99

CHIX:MMTXz's Net Margin % is ranked worse than
82.48% of 942 companies
in the Biotechnology industry
Industry Median: -88.815 vs CHIX:MMTXz: -1542.99

MindMaze Therapeutics Holding  (CHIX:MMTXz) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

MindMaze Therapeutics Holding Net Margin % Related Terms

MindMaze Therapeutics Holding Net Margin % Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding Net Margin % Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
Net Margin %
0.00 -1,542.99

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
Net Margin % 0.00 -1,542.99

CHIX:MMTXZ vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindMaze Therapeutics Holding Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Net Margin % distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's Net Margin % falls into.


CHIX:MMTXZ
15GF Score
MindMaze Therapeutics Holding SA CHIX:MMTXZ
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

MindMaze Therapeutics Holding's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-9.906/0.642
=-1,542.99 %

MindMaze Therapeutics Holding's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-9.906/0.642
=-1,542.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -1,542.99% mean?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a Net Margin % of -1,542.99% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on MindMaze Therapeutics Holding and its competitors. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #777 out of 942 companies in the Biotechnology industry, placing it in the top 82.5%.
Is MindMaze Therapeutics Holding's Net Margin % too high?
MindMaze Therapeutics Holding's current Net Margin % is -1,542.99%. Based on the distribution chart, MindMaze Therapeutics Holding ranks #777 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #777 out of 942 companies for Net Margin %. This places MindMaze Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current Net Margin % is -1,542.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current Net Margin % of -1,542.99%. The current Net Margin % is -1,542.99%. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current Net Margin % is -1,542.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score

Get the complete analysis for CHIX:MMTXZ

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.21
Price